ChemoCentryx Inc., a Mountain View, Calif.-based developer of oral drugs for autoimmune diseases, inflammatory diseases and oncology, has withdrawn registration for a $57.5 million IPO, citing “market conditions.” The company had planned to trade on the Nasdaq, with Credit Suisse serving as lead underwriter.
ChemoCentryx recently raised $50 million from existing investor GlaxoSmithKline, at a higher valuation than on its Series D round in March 2007 ($30m round at a $188m post-money). Overall, the company has raised around $155 million from GSK, OrbiMed Advisors, HBM BioVentures, Alta Partners, HealthCap and GIMV. www.chemocentryx.com
Take your pick!
- Buyouts delivers exclusive news and analysis about private equity deals, fundraising, top-quartile managers and more. Get your FREE trial or subscribe now.
- VC Journal provides exclusive news and analysis about venture capital deals, fundraising, top-quartile investors and more. Get your FREE trial or subscribe now.